Table of Content

1. Introduction


2. Research Methodology


3. Executive Summary


4. Market Dynamics

4.1 Growth Drivers
4.2 Challenges


5. Global Alzheimer’s Drugs Market


6. Global Alzheimer’s Drugs Market Share Analysis

6.1 Drug Class
6.2 Drug Type
6.3 Distribution Channel
6.4 Country


7. Drug Class– Global Alzheimer’s Drugs Market

7.1 Cholinesterase Inhibitors
7.2 NMDA Receptor Antagonist
7.3 Combination Drugs
7.4 Others


8. Drug type – Global Alzheimer’s Drugs Market

8.1 Galantamine
8.2 Donepezil
8.3 Memantine
8.4 Rivastigmine
8.5 Others


9. Distribution Channel – Global Alzheimer’s Drugs Market

9.1 Hospital Pharmacies
9.2 Retail Pharmacies
9.3 Online Pharmacies


10. Country – Global Alzheimer’s Drugs Market

10.1 North America

10.1.1 United States
10.1.2 Canada

10.2 Europe

10.2.1 France
10.2.2 Germany
10.2.3 Italy
10.2.4 Spain
10.2.5 United Kingdom
10.2.6 Belgium
10.2.7 Netherlands
10.2.8 Turkey

10.3 Asia Pacific

10.3.1 China
10.3.2 Japan
10.3.3 India
10.3.4 South Korea
10.3.5 Thailand
10.3.6 Malaysia
10.3.7 Indonesia
10.3.8 Australia
10.3.9 New Zealand

10.4 Latin America

10.4.1 Brazil
10.4.2 Mexico
10.4.3 Argentina

10.5 Middle East & Africa

10.5.1 Saudi Arabia
10.5.2 UAE
10.5.3 South Africa


11. Porter’s Five Analysis – Global Alzheimer’s Drugs Market

11.1 Bargaining Power of Buyers
11.2 Bargaining Power of Suppliers
11.3 Degree of Rivalry
11.4 Threat of New Entrants
11.5 Threat of Substitutes


12. SWOT Analysis – Global Alzheimer’s Drugs Market

12.1 Strength
12.2 Weakness
12.3 Opportunity
12.4 Threat


13. Company Analysis – Global Alzheimer’s Drugs Market

13.1 Abbvie Inc.

13.1.1 Overview
13.1.2 Recent Development
13.1.3 Product Portfolio
13.1.4 Financial Insights

13.2 AstraZeneca PLC

13.2.1 Overview
13.2.2 Recent Development
13.2.3 Product Portfolio
13.2.4 Financial Insights

13.3 Biogen Inc.

13.3.1 Overview
13.3.2 Recent Development
13.3.3 Product Portfolio
13.3.4 Financial Insights

13.4 Eisai Co. Ltd.

13.4.1 Overview
13.4.2 Recent Development
13.4.3 Product Portfolio
13.4.4 Financial Insights

13.5 Eli Lilly and Company

13.5.1 Overview
13.5.2 Recent Development
13.5.3 Product Portfolio
13.5.4 Financial Insights

13.6 H. Lundbeck A/S

13.6.1 Overview
13.6.2 Recent Development
13.6.3 Product Portfolio
13.6.4 Financial Insights

13.7 F. Hoffmann-La Roche AG

13.7.1 Overview
13.7.2 Recent Development
13.7.3 Product Portfolio
13.7.4 Financial Insights

13.8 Merck & Co. Inc.

13.8.1 Overview
13.8.2 Recent Development
13.8.3 Product Portfolio
13.8.4 Financial Insights

13.9 Novartis AG

13.9.1 Overview
13.9.2 Recent Development
13.9.3 Product Portfolio
13.9.4 Financial Insights

13.10 Ono Pharmaceutical Co. Ltd.

13.10.1 Overview
13.10.2 Recent Development
13.10.3 Product Portfolio
13.10.4 Financial Insights

13.11 Pfizer Inc.

13.11.1 Overview
13.11.2 Recent Development
13.11.3 Product Portfolio
13.11.4 Financial Insights

13.12 Teva Pharmaceutical Industries Limited

13.12.1 Overview
13.12.2 Recent Development
13.12.3 Product Portfolio
13.12.4 Financial Insights